Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07459335Completed

TArget Trial Emulation Comparing Effectiveness of Tocilizumab vs Methotrexate In Corticosteroid-Treated GCA Patients

Role: lead

NCT07354906Not Yet Recruiting

Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.

Role: lead

NCT07244614Recruiting

Ustekinumab in BEhçet's Syndrome STudy

Role: lead

NCT06757426Not Yet Recruiting

Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases

Role: lead

NCT06271018Recruiting

TocILizumab in aorTitis in GCA (TILT)

Role: lead

All 5 trials loaded